trending Market Intelligence /marketintelligence/en/news-insights/trending/sb4-7I53eGyRiqTiJ1B47g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aimmune's peanut allergy drug accepted for US FDA review

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aimmune's peanut allergy drug accepted for US FDA review

Aimmune Therapeutics Inc.'s biologics license application for its peanut allergy drug has been accepted for review by the U.S. Food and Drug Administration.

The drug, called AR101, is intended to reduce risk of anaphylaxis — a potentially life-threatening allergic reaction that includes skin rash and difficulty breathing — in children ages 4 to 17 due to accidental exposure to peanut. AR101 received breakthrough designation from the FDA in 2015.

The application is based on a previous successful phase 3 trial, the Brisbane, Calif.-based company said in a March 18 press release.

According to Aimmune, the FDA's review of AR101 could take until January 2020, though Aimmune said it is discussing the review timeline with the agency.

The FDA, which had postponed work on the AR101 filing due to the 35-day government shutdown that began hours after Aimmune submitted its application, will also hold an advisory committee meeting for the potential product.